A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with r... von Chung, Christine H., Colevas, A. Dimitrios Dimitrios, Adkins, Douglas, Rodriguez, Cristina P., Park, Jong Chul, Gibson, Michael K., Burtness, Barbara, Johnson, Faye M., Julian, Ricklie Ann, Saba, Nabil F., Worden, Francis P., Dunn, Lara, Seiwert, Tanguy Y., Jotte, Robert M., Bauman, Julie E., Chaney, Marya F., Margossian, Steven, Levisetti, Matteo, Pai, Sara I.

Volltext

Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC) von Bauman, Julie E., Saba, Nabil F., Roe, Denise, Bauman, Jessica R., Kaczmar, John M., Bhatia, Aarti K., Muzaffar, Jameel, Julian, Ricklie Ann, Wang, Steven, Bearelly, Shethal, Baker, Audrey, Steuer, Conor Ernst, Giri, Anshu, Burtness, Barbara, Centuori, Sara, Caulin, Carlos, Saboda, Kathylynn, Obara, Stefanie, Chung, Christine H.

Volltext

Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden von Sabari, Joshua K., Julian, Ricklie Ann, Ni, Ai, Halpenny, Darragh, Hellmann, Matthew David, Drilon, Alexander E., Li, Bob T., Poirier, John T., Rudin, Charles M., Rekhtman, Natasha

Volltext

Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) von Bauman, Julie E., Roe, Denise, Saba, Nabil F., Bauman, Jessica Ruth, Kaczmar, John M., Burtness, Barbara, Muzaffar, Jameel, Julian, Ricklie Ann, Wang, Steven, Bearelly, Shethal, Baker, Audrey, Steuer, Conor Ernst, Bhatia, Aarti K., Giri, Anshu, Caulin, Carlos, Stabile, Laura P., Centuori, Sara, Chung, Christine H.

Volltext